ETH Zurich Breakthrough: New Drug Delivery System Using Zinc Oxide Particles

In a groundbreaking development, researchers at ETH Zurich have unveiled an innovative drug delivery system using specially designed zinc oxide particles. This Swiss-led research represents a significant advancement in the field of targeted drug delivery, particularly for cancer treatment. The newly discovered particles, which bear a striking resemblance to paper flowers or sand roses, offer a promising alternative to conventional drug delivery methods.

The innovative aspect of this development lies in the unique structure of these 'flower particles.' Unlike traditional gas bubbles used in drug delivery, these zinc oxide particles feature an extensively larger surface area, allowing for greater drug-carrying capacity within the spaces between their 'petals.' The particles can be controlled acoustically using ultrasound, as they effectively scatter sound waves. Additionally, these particles can be coated with light-absorbing molecules, making them easily traceable within the body - a crucial advantage for precise drug delivery applications.

Under the leadership of Daniel Razansky and Metin Sitti, the research team has achieved significant milestones in testing these particles. Initial laboratory experiments in Petri dishes successfully demonstrated the particles' ability to carry cancer drugs. The research progressed to animal trials, where the team successfully used focused ultrasound to guide and capture the particles at specific points in the bloodstream of mice. These preliminary results mark a crucial step toward developing more effective targeted drug delivery systems.

The development of these zinc oxide particles opens new possibilities in targeted drug delivery, particularly for treating cancer and circulatory diseases. Before human applications can begin, the research team plans to conduct further animal studies to ensure safety and efficacy. This Swiss innovation could potentially revolutionize how medications are delivered in the body, reducing side effects and improving treatment outcomes. The precision and traceability of these particles represent a significant step forward in medical technology, showcasing Switzerland's continued leadership in medical research and innovation.